Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Hepatocellular 8Neuroendocrine Tumors 2Neoplasm Metastasis 2Liver Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Sarcoma 1Recurrence 1Rectal Neoplasms 1Ovarian Neoplasms 1Liver Malignancy 1Hepatic Malignancies 1Carcinoma, Ovarian Epithelial 1Bile Duct Neoplasms 1

Interventions

Cyclophosphamide 153Dexamethasone 141Rituximab 85fludarabine 79Lenalidomide 72Cytarabine 70Bortezomib 64fludarabine phosphate 63Gemcitabine 62venetoclax 54Etoposide 53pomalidomide 52pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Yttrium-90 × Clear all
NCT01898962 2013-07-15

Definitive Therapy for Oligometastatic Solid Malignancies

Rocky Mountain Cancer Centers

Phase 2 Unknown
110 enrolled
Sarcoma

Neoplasm Metastasis, Recurrence, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡